French pharma Trophos has reported positive top-line data from its pivotal Phase II/III study of olesoxime in spinal muscular atrophy (SMA), a product the company has resolutely backed despite past setbacks.
French pharma Trophos has reported positive top-line data from its pivotal Phase II/III study of olesoxime in spinal muscular atrophy (SMA), a product the company has resolutely backed despite past setbacks.
Olesoxime, a cholesterol-like compound that targets and preserves mitochondrial integrity and function in stressed cells, was shown to prevent loss...
There is little to divide the Phase III results for the two aldosterone synthase inhibitors, though AstraZeneca’s combination and cardiovascular outcomes studies could bear fruit in the long-term.
The biotech announced positive topline Phase I/II results for the BCL2 inhibitor in late-line mantle cell lymphoma, with Phase III studies underway in chronic lymphocytic leukemia.
Johnson & Johnson will push ahead with its 'pipeline-in-a-product' plans for Imaavy despite pulling the plug on its development in rheumatoid arthritis.
